You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR HYDROXYCHLOROQUINE SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for HYDROXYCHLOROQUINE SULFATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00946790 ↗ To Demonstrate the Relative Bioavailability of Hydroxychloroquine Sulfate, 200 mg Tablets Completed Sandoz Phase 1 1993-07-01 To demonstrate the relative bioavailability of hydroxychloroquine sulfate, 200 mg tablets.
NCT01551069 ↗ Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed Sanofi Phase 3 2012-03-01 Primary Objective: - To investigate the efficacy on skin manifestation of 16 weeks treatment of once daily regimen of hydroxychloroquine sulphate (HCQ) in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active skin manifestation (CLASI [Cutaneous Lupus Erythematosus Disease Area and Severity Index] activity score is ≥4) concomitant treatment with or without corticosteroid. Secondary Objectives: - To evaluate the efficacy on skin manifestation and the safety of 16 weeks treatment of once daily regiment of HCQ versus placebo as the reference group in patients with CLE and SLE with active skin manifestation (CLASI activity score is ≥4) concomitant treatment with or without corticosteroid. - To investigate the safety of 16 weeks treatment of once daily regiment of HCQ in patients with CLE and SLE with active skin manifestation concomitant treatment with or without corticosteroid. - To investigate the safety and efficacy of 52 weeks long-term treatment of once daily regimen of HCQ in patients with CLE and SLE - To investigate the influence of the dose reduction of corticosteroid on CLE and SLE patients treated with HCQ concomitant with corticosteroid - To investigate efficacy of once daily regimen of HCQ on systemic symptoms, musculoskeletal symptoms and immunological parameters in SLE patients.
NCT02351752 ↗ Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Completed LLiu Phase 4 2015-01-01 IgA nephropathy is the most common type of primary glomerulonephritis and might caused by deposition of immune complex containing IgA in mesangium and causing local immune activation. Hydroxychloroquine reduces the activation of dendritic cells and the inflammatory process and showed the potential effect of treatment of patients with IgA nephropathy. The investigators study will recruite IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 300-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.
NCT02615938 ↗ Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD) Suspended Matthias Griese Phase 2 2015-04-01 This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multinational study investigating the initiation or withdrawal of hydroxychloroquine in subjects with chILD.
NCT02765594 ↗ Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Unknown status Peking Union Medical College Hospital Phase 4 2016-06-01 Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world.There is to date no curative therapy for patients with IgAN.It is considered that dendritic cells, Toll-like receptor (TLR) 9 and cytokines interleukin-6 (IL-6), and interferon-alpha (IFN-a) and tumor necrosis factor-alpha (TNF-α), play an important role in the aberrant mucosal response. Hydroxychloroquine is an antimalarial agent and had a notable impact on immune activation by the reduction of circulating activated immune cells that including decreased TLR-expressing cells, reduced IFN-secreting plasmacytoid dendritic cells, reduced production of inflammatory cytokines including interferon alpha, IL-6 and TNF alpha. Recent studies showed hydroxychloroquine had a benefit for renal remission and could retard the onset of renal damage in patients with lupus nephritis. hydroxychloroquine may have the potential effect in IgA nephropathy, alleviated the proteinuria and had the renal protect effect. This will be a single center, prospective, randomized, controlled study to assess the utility of hydroxychloroquine in IgAN patients.
NCT02942381 ↗ A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy Completed Peking University First Hospital Phase 2 2016-09-13 The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for HYDROXYCHLOROQUINE SULFATE

Condition Name

Condition Name for HYDROXYCHLOROQUINE SULFATE
Intervention Trials
COVID-19 13
Covid19 4
Hydroxychloroquine 3
SARS-CoV-2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for HYDROXYCHLOROQUINE SULFATE
Intervention Trials
COVID-19 29
Coronavirus Infections 9
Severe Acute Respiratory Syndrome 7
Infection 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for HYDROXYCHLOROQUINE SULFATE

Trials by Country

Trials by Country for HYDROXYCHLOROQUINE SULFATE
Location Trials
United States 29
Germany 8
China 6
Thailand 3
Brazil 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for HYDROXYCHLOROQUINE SULFATE
Location Trials
New York 4
Massachusetts 3
New Jersey 3
Pennsylvania 2
Washington 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for HYDROXYCHLOROQUINE SULFATE

Clinical Trial Phase

Clinical Trial Phase for HYDROXYCHLOROQUINE SULFATE
Clinical Trial Phase Trials
Phase 4 6
Phase 3 9
Phase 2/Phase 3 4
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for HYDROXYCHLOROQUINE SULFATE
Clinical Trial Phase Trials
Completed 13
Recruiting 12
Active, not recruiting 5
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HYDROXYCHLOROQUINE SULFATE

Sponsor Name

Sponsor Name for HYDROXYCHLOROQUINE SULFATE
Sponsor Trials
Rutgers, The State University of New Jersey 3
Bill and Melinda Gates Foundation 2
University of Washington 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for HYDROXYCHLOROQUINE SULFATE
Sponsor Trials
Other 97
Industry 10
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.